About the Study
This research study is assessing the effectiveness of a weight-loss medication called Tirzepatide (also known as Mounjaro or Zepbound) in young adults with Prader-Willi Syndrome, compared with young adults with obesity unrelated to a genetic syndrome or underlying medical cause.
This is a 48-week trial that includes 6 in-person study visits, 4 telehealth visits, and an additional visit 8 weeks after stopping the medication. Study participants will be given medication for 1 year to assess how the medication affects weight and other health factors.
Participants will receive a $50 gift card per visit, as well as Tirzepatide for 1 year.
Eligibility Criteria
This study is enrolling 12 individuals:
-
18-26 years old
-
Diagnosed with Prader-Willi Syndrome
-
BMI in the obesity range (BMI >/= 30)
This Study is enrolling at the following 3 sites:
Vanderbilt University Medical Center
Principal Investigator: Ashley Shoemaker, MD
Contact: Martha Upchurch
Phone: 615-875-4274
Email: martha.upchurch@vumc.org
Children's Hospitals and Clinics of Minnesota
Principal Investigator: Jennifer Abuzzahab, MD
Contact: Diabetes/Endocrinology Research Team
Phoen: 651-220-5730
Email: endocrineresearch@childrensmn.org
Seattle Children's Hospital
Principal Investigator: Grace Kim, MD
Contact: Diabetes/Endocrinology Research Team
Phone: 206-987-2540
Email: EndocrineResearch@seattlechildrens.org
More information can be found on clinicaltrials.gov: study ID NCT06901245
